OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Onkure Therapeutics Inc OKUR
$3.37
โฒ +5.64%
(+$0.18)
⬆️ Above Yest. High
Open
$3.12
Prev Close
$3.19
Day Range
$2.99 โ $3.41
52W Range
$2.01 โ $5.38
Market Cap
$129.20M
Beta
0.09
EPS (TTM)
$-3.50
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-04-09 |
| Shares Out. | 40,500,000 |
| Website | onkuretherapeutics.com/ โ |
| Phone | 13026587581 |
| Employees | 45 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$17.8M |
| Free Cash Flow | -$47.9M |
| Total Assets | $167.1M |
| Total Liabilities | $9.3M |
| Equity | $157.7M |
About Onkure Therapeutics Inc
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kฮฑ. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Onkure Therapeutics Inc is a publicly traded company under the ticker symbol OKUR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
11 analysts (2026-11-01)